Penumbra said last week that a study of its Ace64 thrombectomy system shows the device to be effective in patients with acute ischemic stroke. The data from the study was presented at the Society of NeuroInterventional Surgery’s annual meeting in San Francisco.
The 117-patient, 6-country study reported a 96% revascularization rate in acute ischemic stroke patients with large vessel occlusions and a 62% revascularization rate in patients with thrombolysis in cerebral infarction, according to Penumbra.
“The multi-center European experience has demonstrated the effectiveness of Ace64. The innovative technology of the Ace64 allows reliable, easy tracking of a large bore aspiration catheter. By using Ace64 direct aspiration frontline, we achieve high revascularization rates and save on procedural cost while still maintaining the option to use adjunctive devices if needed. Ace64 is not only effective but also a very versatile stroke platform,” Dr. Blaise Baxter of Tennessee’s Erlanger Hospital said in a press release.
The study reported a procedure time of 35 minutes when using the Ace64 and a modified Rankin Scale of 46% at discharge, the company said.
“We were able to show that Ace64 achieved high revascularization rates, particularly TICI 3 scores. In Europe, my colleagues and I have long used many different variations of stent retrievers. Ace64 offers improvements over earlier technology by quickly removing clot en masse, often in a single attempt, to increase TICI 3, reduce procedure time and minimize the need for adjunctive devices. Working proximal to the occlusion, Ace64 also decreases clot disruption to create a favorable safety profile,” study investigator Dr. Werner Weber of Bochum, Germany’s University Hospital Knappschaftskrankenhau.